AstraZeneca’s (AZN) “Buy” Rating Reiterated at Shore Capital

Shore Capital reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a report issued on Thursday, Marketbeat.com reports. Shore Capital currently has a £145 price target on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on AZN. Berenberg Bank increased their price target on AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Monday, October 13th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £110 price target on shares of AstraZeneca in a research report on Wednesday, July 30th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of £135.

AstraZeneca Stock Up 0.4%

AZN stock opened at £128.85 on Thursday. The firm’s fifty day simple moving average is £121.57 and its 200-day simple moving average is £112.36. The company has a market capitalization of £199.75 billion, a P/E ratio of 24.27, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 12 month low of GBX 9,573.51 and a 12 month high of £129.94.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Aradhana Sarin sold 9,563 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of £115.12, for a total transaction of £1,100,892.56. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.